Epclusa

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0032/G	This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch	29/01/2019	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

	control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place				
PSUSA/10524 /201806	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir	17/01/2019	n/a		PRAC Recommendation - maintenance
IG/1037	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	14/12/2018		SmPC and PL	
WS/1476	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study GS-US-334-0154, listed as a category 3 study in the RMP. This is a phase 2b randomized, open-label study of 200mg or 400mg sofosbuvir + ribavirin for 24 Weeks in genotype 1 or 3 HCV-infected subjects with renal insufficiency. The RMPs have also been submitted for each of the products in this work-sharing procedure. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	29/11/2018	n/a		
PSUSA/10524 /201712	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir	12/07/2018	n/a		PRAC Recommendation - maintenance

WS/1391	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.3 of the SmPC based on data from a 2-year rat carcinogenicity study TX-281-2030. In addition, the MAH took the opportunity to update the ATC code in line with the new classification of antivirals for treatment of HCV infections and to introduce minor linguistic amendments and typographical corrections throughout the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/06/2018		SmPC and PL	Velpatasvir was not carcinogenic in the 2-year rat carcinogenicity study at exposures at least 5-times higher than human exposure.
T/0027	Transfer of Marketing Authorisation	25/04/2018	28/05/2018	SmPC, Labelling and PL	
IG/0901	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	26/03/2018	n/a		
IB/0023	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	13/02/2018	28/05/2018	SmPC	
WS/1328/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of	08/02/2018	n/a		

	the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits				
WS/1272	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation	18/01/2018	n/a		
PSUSA/10524 /201706	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir	11/01/2018	n/a		PRAC Recommendation - maintenance
IB/0022/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.f.1.e - Stability of FP - Change to an approved stability protocol	09/01/2018	n/a		
IB/0019	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	15/12/2017	n/a		
WS/1246/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	30/11/2017	n/a		

	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation				
IG/0848/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	12/10/2017	n/a		
IG/0840/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or	22/09/2017	n/a		

	intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits				
II/0012	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/09/2017	30/10/2017	SmPC	Velpatasvir was not carcinogenic in the 6-month rasH2 transgenic mouse study at exposures at least 50 times higher than human exposure. A carcinogenicity study in rats is ongoing.
IB/0014	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	15/08/2017	n/a		

IB/0013	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	20/07/2017	n/a		
PSUSA/10524 /201612	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir	06/07/2017	n/a		PRAC Recommendation - maintenance
IB/0011/G	This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.1.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a Union referral procedure - The product is not covered by the defined scope of the procedure but the change(s) implements the outcome of the procedure and no new additional data is required to be submitted by the MAH	25/05/2017	30/10/2017	SmPC, Annex II and PL	
IAIN/0010/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	18/04/2017	n/a		

WS/1075	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	23/03/2017	n/a		
II/0003	Update of section 5.1 of the SmPC in order to reflect on emerging clinical data from study GS-US-342-1202 investigating efficacy and safety in subjects with chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1 coinfection. In addition, minor editorial changes are implemented throughout the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	23/02/2017	30/10/2017	SmPC and PL	The CHMP, having reviewed the results from the clinical study GS-US-342-1202, considered that section 5.1 of the SmPC should be updated with regards to the newly available data regarding patients with chronic hepatitis C and HIV co-infections. No updates to the Package Leaflet were considered necessary based on these data. An editorial update was implemented in section 2 of the Package Leaflet to align it with the existing information in the SmPC that Epclusa should be taken with food 4 hours before using a proton pump inhibitor.
WS/1104	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	16/02/2017	n/a		
IG/0748	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	28/11/2016	30/10/2017	SmPC and PL	

IB/0005/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	17/11/2016	n/a		
WS/1035/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a	10/11/2016	n/a		

	starting material/reagent/intermediate for AS - Other variation				
IB/0001	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	19/09/2016	n/a		